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ABSTRACT
All transplant patients are at increased risk of developing pulmonary infections, a
significant cause of morbidity and mortality. Immunosuppressants increase the incidence
of lung infection by acting not only directly on the inflammatory cells, but also on the
native immune system. Experimental studies have shown corticosteroid therapy, which is
used in most immunosuppressive protocols after transplantation, to suppress mucus
production by inhibiting calceiform. The objective of this study was to evaluate the effects
of prednisone on mucociliary clearance. A total of 120 male Wistar rats were distributed
into 4 groups. Animals in P1, P2, and P3 groups received daily doses of prednisone (0.625,
1.25, and 2.5 mg/kg/d), and hosts in the Sal group underwent gavage with saline solution
(2.5 mL/d). After 7, 15, and 30 days, treatment, animals were killed. We assessed ciliary
beating frequency (CBF), mucociliary transport velocity (MCTV), and mucus transport-
ability (MT). There was no significant difference for CBF regarding dose (P  .089) or
treatment duration (P  .175). MCTV values of 0.60  0.14 in group P1, 0.59  0.13 in
group P2, 0.51  0.19 in group P3, and 0.61  0.08 Group Sal, showed P3 to significantly
differ from P1 (P  .048) and Sal (P  .007) groups. Regardless of the prednisone dose,
all groups displayed impaired MT compared with the Sal group: P1 (P .02); P2 (P .02)
P3 (P  .03). There was no interaction between the therapy and the treatment time for
CBF (P  .10), MCTV (P  .71), and MT (P  .64). Prednisone reduced the
transportability of mucus even when administered at low doses; however, this change was
not sufficient to alter the mucociliary clearance. Only high doses of prednisone impaired
mucociliary clearance.Transplant patients are at increased risk of developingpulmonary infections, a significant cause of morbidity
and mortality. The lungs of transplant candidates may have
been exposed to toxic insults from their underlying diseases,
infections, or chemotherapy, which can alter surveillance
barriers. Moreover, surgical procedures and ventilatory sup-
port for organ transplant patients may impair native defenses,
increasing the risk for pulmonary infections.1–3 Mucociliary
clearance (MCC), which plays an important role in human
defense mechanisms, is subject to this impairment.4
The incidence of pneumonia is highest among heart,
lung, and heart-lung transplantations.5,6 Aspergillus pneu-
onia occurs in 5%–8% of recipients, with a high mortal-
ty.6 In liver transplantation, postoperative pneumonias,
usually due to a gram-negative organism such Pneumococ-
cus aeruginosa, show significant mortality. Kidney trans-
plants have the best survival and the lowest rate of pneu-
monia. Nonetheless, bacterial and viral infections are in
associated with graft loss.7
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2486Immunosuppressive drugs are used either as preventative
agents for acute rejection or to maintain a steady immu-
nodepressed state. During maintenance treatment, 2 factors
are critical: optimizing graft function, and minimizing ad-
verse reactions to immunosuppressants. Immunosuppres-
sive therapy generally includes several simultaneously ad-
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PREDNISONE AND MUCOCILIARY CLEARANCE 2487ministered drugs with different mechanisms of action and
toxicities.
Immunosuppressants increase the incidence of lung in-
fections, by acting not only directly to modulate inflamma-
tory cells, but also on the native immune system. Studies
have demonstrated that immunosupressive agents, such as
cyclosporine and mycophenolate, impair mucociliary trans-
port velocity (MCTV).8–10 This impairment has been at-
tributed to alterations in viscoelastic properties of mucus
produced in the affected bronchial region. Impaired ciliary
epithelium has also been reported in stem cell transplant
patients; it may persist for years.
Corticosteroids such as prednisone, are used in most
maintenance and antirejection immunosuppressive proto-
cols. However, they have a wide side effect profile to
increase the risk of fungal and bacterial infections. It is
known that prednisone decreases gene expression related to
the production of proteins found in the mucociliary epithe-
lium.11 Experimental studies have shown that corticosteroid
therapy, such as betamethasone, suppresses mucus produc-
tion by inhibiting calceiform cells and may also reduce
proinflammatory cytokines that stimulate mucus produc-
tion.12,13 The literature does not refer to studies on the
ffects of systemic corticosteroids on mucociliary function.
ecause MCC plays an important role in human defense
echanisms, we sought to examine the influence of drugs
n MCC of patients undergoing transplantation.
METHODS
This research was approved by the Ethical Committee of our
institution. All animals were treated in agreement with the Brazil-
ian regulations for the use of animals in scientific research.
Experimental Animals
The 120 maleWistar rats were distributed into 4 groups. Animals in
P1, P2, and P3 groups received doses of prednisone (0.625, 1.25,
and 2.5 mg/kg/d, respectively); those in the Sal group received
gavage of saline solution (2.5 mL/d). After 7, 15, and 30 days of
treatment, animals were killed, to assess ciliary beating frequency
(CBF), MCTV, and mucus transportability (MT). All procedures
were performed according to the guidelines of the Institutional
Animal Care and Use Committee at the University of Pittsburgh
and the National Research Council’s Guide for the Humane Care
and Use of Laboratory Animals.14
Gavage
Daily gavage was performed via the orogastric route with a number
7 polyethylene catheter. Animals were sedated in a closed chamber
containing inhaled isoflurane anesthetic (Isothane, Baxter). The
test solution was prepared by dissolving and homogenizing a 5 mg
prednisone tablet into 10 mL saline solution (0.9%), resulting in a
dose-volume of 1.25 mL/kg/d for P1 group, 2.5 mL/kg/d for P2, and
5 mL/kg/d for P3. Animals in Sal group daily received a volume
corresponding to 2.5 mL/kg/d 0.9% saline solution.
Killing the Animals
After 7, 15, and 30 days of treatment, 10 animals in each group
were anesthetized with intraperitoneal pentobarbital (50 mg/kg)and killed by exsanguination, according to the Report of the
American Veterinary Medicine Association Panel on Euthanasia.16
Mucociliary Clearance Analysis
After the lungs were removed from the thoracic cavity, we per-
formed an incision in the left main stem bronchus to collect mucus
samples. In vitro mucus transportability was evaluated with the use
of a bullfrog (Rana catesbeiana) palate model, as follows. The
transport velocity of the mucus sample placed on an excised frog’s
palate was determined with the aid of a stereomicroscope equipped
with a reticulated eyepiece. The velocity of the rat mucus samples
was compared with the transport speed of autologous frog mucus;
the results were expressed as relative speed (rat/frog). After mucus
sample collection, the ventral wall of the left main stem bronchus
was opened to expose the ciliated epithelium. The bronchus was
placed under a light microscope (BX50; Olympus, Tokyo, Japan)
connected to a camera (Triniton 3CCD, Sony, Tokyo, Japan). A
stroboscope (Machine Vision Strobe, Cedarhurst, NY) placed in
front of the bronchus allowed CBF to be measured by synchroni-
zation between cilia movement and the stroboscopic flashlight.
Then, under the same microscope, we estimated in situ MCT by
direct observation of the time for a talc particle to move across the
bronchus.
Data Presentation and Statistical Analysis
A double-factor variance analysis were used to evaluate the
influence of the analyzed factors on the dependent variables, as
well as their possible interactions, followed by a post hoc Bonfer-
roni test for multiple analyses among groups. Normality and
homogeneity were evaluated in the group by Kolmogorov-Smirnov
test with Lilliefors correction (P  .05 for all groups) and Levene
test (P  .05). Descriptive and inferential statistical analyses were
performed with SPSS software version 13 (SPSS 13.0 for Win-
dows).
RESULTS
The CBF values of (9.71  1.04 in group P1, 9.18  1.15 in
group P2, 9.16 1.13 in group P3, and 9.59 0.81 in group
al, showing slight variations regarding dose and treatment
uration, did not achieve statistical significance (P  .089;
nd P  .175; respectively).
The MCTV of 0.60  0.14 in group P1, 0.59  0.13 in
group P2, 0.51  0.19 in group P3, and 0.61  0.08 group
Sal showed P3 to significantly differ from P1 (P  .048) and
Sal (P  .007) groups. However, P3 was not different from
P2 (P  .066) (Fig 1). Further comparisons among groups
did not present a significant difference (P 1.00). Data also
showed there was no difference regarding times of therapy:
7, 15, or 30 days (P  .095).
The prednisone therapy, groups regardless of dose,
showed impaired MT compared with the Sal group (Fig 2).
The Sal group was significantly different from P1 (P  .02),
P2 (P  .02), and P3 (P  .03). The therapy time did not
influence MT (P  .719).
There was no interaction between the therapy and the
treatment time among the 3 variables: CBF (P  .10),
MCTV (P  .71), and MT (P  .64).
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Lungs are remarkably resistant to environmental injury,
despite continuous exposure to pathogens, particles, and
toxic chemicals in inhaled air. Mucociliary epithelium is the
first line of lung defense. The mucus gel is propelled in a
proximal direction by ciliary beating, clearing inhaled par-
ticles, pathogens, and dissolved chemicals that might dam-
age the lungs. Pulmonary resistance depends on a highly
effective defense provided by airway mucus which traps
inhaled toxins and transports them out of the lungs by
means of ciliary beating and cough. Paradoxically, although
a deficient mucous barrier leaves the lungs vulnerable to
injury, both excessive mucus and impaired clearance con-
tribute to the pathogenesis of all common airway diseases.15
Overall survival after solid organ transplantation has
significantly increased over the past several years owing to
the development of improved surgical techniques, new
immunosuppression protocols, and prophylactic strategies.
However, pulmonary infection is a significant cause of
morbidity and mortality. It is known that the risk of
infectious complications is maximal during the first month
after transplantation.
Several factors involved in the surgical procedure and
postoperative management can impair mucociliary epithe-
lium. Various mechanical ventilation strategies induce mor-
phologic and physiologic tracheal alterations leading to
mucociliary transport dysfunction.2 Cyclosporine impairs
MCTV by acting on the mucus viscoelastic properties.9,10
Prednisone, the most widely used corticosteroid in immu-
nosuppressive protocols after solid organ transplantation, It
alters mucin gene expression,11,12 and we probably affects
MCC, increasing the chances of lung infection.
The literature does not refer to studies on the effects of
systemic corticosteroid use in mucociliary function, but it is
known that prednisone decreases gene expression related to
the production of proteins found in the mucus.11,12 Exper-
mental studies have shown that corticosteroid therapy,
uch as well betamethasone, may suppress mucus produc-
ion by inhibiting calceiform cells and may also reduce
Fig 1. Mucociliary transport velocity of animals treated with
different doses of prednisone (P1, P2, and P3) or saline solution
at 0.9% (Sal). P3 group had a statistically significant difference
compared with P1 (*P  .048) and Sal (#P  .007).roinflammatory cytokines that stimulate mucus produc-ion.12,13 Changes in protein production that modify mucus
characteristics are directly related to impairment of its
transportability. In addition, mucus accumulation can lead
to infection and inflammation by providing an environment
for microbial growth.
In the present study, we observed that prednisone at all
study doses interferes in dose-dependent fashions with
mucus quality by reducing its transportability. This obser-
vation indicated that prednisone changes mucus features
even when administered at low doses.
Perfect MT function depends on multiple interactions
including intact ciliated epithelium with synchronized cili-
ary beating, an adequate amount of mucus with ideal
viscoelastic properties, and an adequate composition and
size of the periciliary fluid layer. Drugs may alter this
process, so it is necessary to know the effect of the drugs on
MCC and its clinical repercussions. Indeed, agents stimu-
lating MCC may be used therapeutically in respiratory
medicine, especially for patients suspected of having im-
paired mucociliary transport systems. We think that the
production of mucus was altered in animals treated with
prednisone leading to decreased mucus transportability.
However, further studies are required to assess the mech-
anisms involved in this interference.
Mucus contains mucin including glycoprotein such as
fucose which is produced by submucosal glands and falci-
form cells, and IgG may determine viscosity and elasticity
from mucus samples.16 Treatment of asthmatic patients
ith corticosteroids has been reported to reduce mucin
roduction and improve mucociliary transportability. These
ffects are taking into consideration that inflammation in
nimal models shows mucus hypersecretion and therefore
educed transportability.15,17 Although the mechanisms are
ot completely understood, it is known that IgG increases
ucus viscoelasticity. Therefore, control of inflammatory
rocesses reduces viscoelasticity in response to a fall in the
gG content of the mucus.16 In these cases, prednisone
mproves the general inflammatory conditions of patients.
ur study used animals free of diseases, whose only condi-
ion was daily treatment with steroids; in this case, the drug
mpaired MT.
Fig 2. Mucus transportability (MT) of animals treated with
different doses of prednisone (P1, P2, and P3) or saline solution
at 0.9% (Sal). Animals treated with prednisone showed a signif-
icant reduction of MT versus Sal group (*P  .03).
PREDNISONE AND MUCOCILIARY CLEARANCE 2489The major difficulty in studying respiratory mucus is the
lack of simple less invasive methods to collect sufficient
amounts of respiratory secretions. We had planned to
characterize the rheologic properties of mucus by measur-
ing the contact angle between mucus and the respirator
surface. However, implementation of the plan was not
possible owing to the small amount of mucus. Despite the
availability of a viscometer, the study in rats also limited its
use owing to the small amount of mucus available. These
techniques may elucidate in greater detail the changes in
the transportability of mucus. However, they can be imple-
mentation in a layer animal model.
In vitro investigations evaluating the influence of topical
corticosteroids such as budesonide have shown a reduction
in CBF by the respiratory mucosa of treated animals.
However, that work has suggested that the damage to the
mucociliary system was more related to the preservative
solutions in the medication, such as benzalconium chloride,
rather than to the corticosteroids themselves.18,19
Alterations in MT of animals treated with prednisone
might indicate impaired MCTV. However, we did not
observe functional effects on MCTV were among groups
treated with lower steroid doses (0.625 mg/kg/d or 1.25
mg/kg/d). The 2.5 mg/kg/d dose exerted a negative effect on
this variable, impairing MCC compared with control ani-
mals or with those receiving 0.625 mg/kg/d.
In general, we noticed that prednisone, despite impairing
mucus transportability, did not affect MCC. Only high doses
may, in addition to impairing MT, reduce MCTV and
consequently local clearance.
In conclusion, prednisone changed the characteristics of
mucus, but did not influence CBF. Even when administered
at low doses, it reduced the transportability of mucus;
however, this change was not sufficient to alter the MCC
which only occurred at high doses.
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